Is GE Healthcare Technologies, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for GE Healthcare Technologies, Inc. changed from attractive to very attractive, indicating a strong positive outlook. The company appears undervalued based on its current metrics, with a P/E ratio of 14, an EV to EBITDA ratio of 11.16, and a PEG ratio of 0.39, all suggesting that the stock is trading at a discount relative to its earnings growth potential. In comparison, peers such as Edwards Lifesciences Corp. have a significantly higher P/E ratio of 31.17, while Agilent Technologies, Inc. has a P/E of 27.42, reinforcing the notion that GE Healthcare is undervalued within its industry.
Despite recent challenges, including a year-to-date return of -5.28% compared to the S&P 500's 13.30%, the company's strong ROE of 25.79% and ROCE of 18.89% highlight its operational efficiency and profitability. This, combined with the favorable valuation ratios, supports the conclusion that GE Healthcare Technologies, Inc. is positioned well for future growth and remains an attractive investment opportunity.